- Home
- BRT vs TNGX Comparison
BRT vs TNGX Comparison
Compare BRT & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRT
- TNGX
- Stock Information
- Founded
- BRT 1972
- TNGX 2014
- Country
- BRT United States
- TNGX United States
- Employees
- BRT N/A
- TNGX N/A
- Industry
- BRT Real Estate Investment Trusts
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- BRT Real Estate
- TNGX Health Care
- Exchange
- BRT Nasdaq
- TNGX Nasdaq
- Market Cap
- BRT 298.3M
- TNGX 351.2M
- IPO Year
- BRT N/A
- TNGX N/A
- Fundamental
- Price
- BRT $15.26
- TNGX $5.88
- Analyst Decision
- BRT Strong Buy
- TNGX Strong Buy
- Analyst Count
- BRT 1
- TNGX 6
- Target Price
- BRT $21.00
- TNGX $12.20
- AVG Volume (30 Days)
- BRT 34.2K
- TNGX 2.6M
- Earning Date
- BRT 08-05-2025
- TNGX 08-06-2025
- Dividend Yield
- BRT 6.51%
- TNGX N/A
- EPS Growth
- BRT N/A
- TNGX N/A
- EPS
- BRT N/A
- TNGX N/A
- Revenue
- BRT $98,162,000.00
- TNGX $40,990,000.00
- Revenue This Year
- BRT $0.36
- TNGX N/A
- Revenue Next Year
- BRT $5.65
- TNGX N/A
- P/E Ratio
- BRT N/A
- TNGX N/A
- Revenue Growth
- BRT 2.71
- TNGX 10.09
- 52 Week Low
- BRT $14.61
- TNGX $1.03
- 52 Week High
- BRT $20.22
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- BRT 46.66
- TNGX 73.28
- Support Level
- BRT $15.46
- TNGX $5.75
- Resistance Level
- BRT $16.20
- TNGX $6.40
- Average True Range (ATR)
- BRT 0.34
- TNGX 0.50
- MACD
- BRT -0.03
- TNGX -0.03
- Stochastic Oscillator
- BRT 31.03
- TNGX 83.80
About BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.